NCT04790409 2023-09-14Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon MutationsZhejiang Cancer HospitalPhase 2 Completed21 enrolled
NCT03607539 2023-02-27Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLCInnovent Biologics (Suzhou) Co. Ltd.Phase 3 Completed397 enrolled 15 charts